Abstract: A method of conducting a biological assay, comprises obtaining data corelative to a temperature of a reagent, mixing the reagent with a sample to provide a mixture, receiving from the mixture a signal indicative of an amount of an analyte in the sample, and correcting the amount based on the obtained data and on a type of the reagent.

Abstract: A method of diagnosing an infectious disease, including determining the severity of the disease, in a subject comprising measuring an expression level of at least one protein selected from the group consisting of TSG-14, AGER, ANG-2 and ST2 in a sample of the subject; and diagnosing the disease based on said expression level. Kits for carrying out the diagnosis are also disclosed.

Abstract: A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

Abstract: In a cartridge device for analyzing a body liquid, a first member of the cartridge has two or more wells for performing assays, and a second member of the cartridge has a compartment for holding one or more disposable pipette tips.

Abstract: A method of selecting an exon of an RNA whose expression level is informative with respect to infection type of a subject is disclosed. The method comprises comparing the expression level of the RNA in a sample derived from a bacterially-infected subject and a sample derived from a virally-infected subject at a plurality of exons, wherein the exon that provides a differential expression between the bacterially-infected subject and the virally-infected subject above a predetermined level is selected as the exon of the RNA whose expression is informative with respect to infection type.

Abstract: A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

Abstract: A method of selecting an exon of an RNA whose expression level is informative with respect to infection type of a subject is disclosed. The method comprises comparing the expression level of the RNA in a sample derived from a bacterially-infected subject and a sample derived from a virally-infected subject at a plurality of exons, wherein the exon that provides a differential expression between the bacterially-infected subject and the virally-infected subject above a predetermined level is selected as the exon of the RNA whose expression is informative with respect to infection type.

Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.

Abstract: A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.

Abstract: A method of analyzing biological data is disclosed. The method comprises obtaining biological data containing at least an expression level of MX dynamin-like GTPase 1 (MX1) and an expression level of C-reactive protein (CRP) in the blood of a subject, calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction, and correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection.

Abstract: Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

Abstract: Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.

Abstract: Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

Abstract: Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

Abstract: In a cartridge device for analyzing a body liquid, a first member of the cartridge has two or more wells for performing assays, and a second member of the cartridge has a compartment for holding one or more disposable pipette tips.

Abstract: A method of classifying an infectious disease in a subject are disclosed. The method comprises: (a) measuring the amount of at least one protein set forth in Table 4 and at least one protein set forth in Table 6 in a sample derived from the subject; and (b) ruling in or ruling out a viral disease based on the amount of the at least one protein set forth in Table 4 and determining the severity of the viral disease based on the amount of the at least one protein set forth in Table 6.

Abstract: In a cartridge device for analyzing a body liquid, a first member of the cartridge has two or more wells for performing assays, and a second member of the cartridge has a compartment for holding one or more disposable pipette tips.

Abstract: Methods of determining infection type are disclosed based on the amount of CD177 RNA and the amount of IFI44L RNA in a sample obtained from the subject. Additional RNA markers for determining infection type are also disclosed. Kits capable of determining infection type are also disclosed.

Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.